Liraglutide, the once-daily human GLP-1 analogue, has a protracted profile based on both delayed absoprtion and a long plasma half-life

被引：0
|
作者：
Knudsen, L. Bjerre [1 ]
Nielsen, P. F. [1 ]
Steensgaard, D. B. [1 ]
Bloch, P. [1 ]
Lau, J. [1 ]
Agersoe, H. [1 ]
机构：
[1] Novo Nordisk AS, Malov, Denmark
来源：
DIABETOLOGIA | 2009年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
775
引用
收藏
页码：S305 / S306
页数：2
相关论文
共 50 条
  • [21] Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
    Horowitz, Michael
    Flint, Anne
    Jones, Karen L.
    Hindsberger, Charlotte
    Rasmussen, Mads F.
    Kapitza, Christoph
    Doran, Selena
    Jax, Thomas
    Zdravkovic, Milan
    Chapman, Ian M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (02) : 258 - 266
  • [22] Pharmacokinetic modelling of the once-daily human GLP-1 analogue liragiutide in healthy volunteers and comparison to exenatide
    Jonker, Daniel
    Toft, Anders D.
    Kristensen, Peter
    Knudsen, Lotte
    Watson, Estelle
    DIABETES, 2007, 56 : A160 - A160
  • [23] Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass
    Meier, J. J.
    Vilsboll, T.
    Donsmark, M.
    Hartvig, H.
    Nauck, M. A.
    DIABETOLOGIA, 2011, 54 : S322 - S322
  • [24] Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
    Horowitz, M.
    Vilsboll, T.
    Zdravkovic, M.
    Hammer, M.
    Madsbad, S.
    DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 593 - U4
  • [25] Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase
    Bjornsdottir, I.
    Olsen, A.
    Larsen, U.
    Helleberg, H.
    Vanggaard, J.
    Oosterhuis, B.
    van Lier, J.
    Zdravkovic, M.
    Malm-Erjefalt, M.
    DIABETOLOGIA, 2008, 51 : S356 - S356
  • [26] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 843 - 854
  • [27] Liraglutide, a once-daily human GLP-1 analog, significantly improves β-cell function in subjects with type 2 diabetes
    Matthews, David
    Marre, Michel
    Le-Thl, T. U. Duyen
    Zdravkovic, Milan
    Simo, Rafael
    DIABETES, 2008, 57 : A150 - A151
  • [28] The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
    Lykkegaard, Kirsten
    Larsen, Philip J.
    Vrang, Niels
    Bock, Camilla
    Bock, Troels
    Knudsen, Lotte Bjerre
    SCHIZOPHRENIA RESEARCH, 2008, 103 (1-3) : 94 - 103
  • [29] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2012, 36 : 843 - 854
  • [30] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (vol 36, pg 890, 2012)
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Roessner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 890 - 890
12345